Support line (toll-free) (844) 835-4325 | Events help (608) 828-8852 | Community

Free To Breathe - A Partnership For Lung Cancer Survival

participant Login


Featured Clinical Trial of the Week: Finding Effective Combination Therapies for Advanced NSCLC

  • February 15 2013

    Share |
    Featured Clinical Trial of the Week: Finding Effective Combination Therapies for Advanced NSCLC

    Every lung cancer clinical trial is conducted in multiple phases. Before the efficacy of a drug, treatment or detection method can be truly evaluated, researchers must establish safety measures and collect data that help them design the best tests.

    Ultimately, doctors conducting this clinical trial want to know whether a new approach at treating lung cancer—blocking the mTOR pathway, which is frequently inappropriately activated in cancer—will be effective.  

    This clinical trial is a phase 1 study, meaning researchers will determine safe dosage ranges and identify side effects to help shape later phases of the trial. Participants will be divided into groups that receive different drug combinations at varying dosages for certain periods of time. All of the groups will receive mTOR kinase inhibitor CC-223. One group of patients will also receive erlotinib (Tarceva®), a drug commonly prescribed for lung cancer patients. Two groups of patients will also receive oral azacitidine, a drug that kills rapidly dividing cells. One group of patients receiving azacitidine will get the drug at the same time as the CC-223 drug, and one group will get azacitidine before they take CC-223.

    Stage IIIB and stage IV non-small cell lung cancer patients with tumor progression after at least one prior treatment regimen are eligible for this trial. Visit for further eligibility and enrollment information.

    If you’re looking for information on other lung cancer clinical trials, please contact our Clinical Trials Matching Service, where trained representatives will match your particular cancer and health issues to clinical trials that are available for you.


Leave a comment

Comment Guidelines

Basic HTML formatting permitted -
<ul>, <li>, <strong>, <em>, <a href>, <blockquote>, <code>

©2018 Lung Cancer Research Foundation | Federal Tax ID #14-1935776 | LCRF is a 501(c)(3) public charity.